Cydanco.com

Cydanco.com has Server used 52.86.62.179 IP Address with Hostname in United States. Below listing website ranking, Similar Webs, Backlinks. This domain was first 2012-12-18 (8 years, 272 days) and hosted in Ashburn United States, server ping response time 31 ms

DNS & Emails Contact

This tool is used to extract the DNS and Emails from this domain uses to contact the customer.

Fetching Emails ...

Extract All Emails from Domain

Top Keywords Suggestions

Keywords suggestion tool used Cydanco keyword to suggest some keywords related from this domain. If you want more, you can press button Load more »

1 Cydanco
2 Cydacorp
3 Cydancewear

Hosting Provider

Website: Cydanco.com
Hostname: ec2-52-86-62-179.compute-1.amazonaws.com
Country:
Region: VA
City: Ashburn
Postal Code: 20147
Latitude: 39.018001556396
Longitude: -77.539001464844
Area Code: 703
Email AbuseNo Emails Found

Find Other Domains on Any IP/ Domain


New! Domain Extensions Updated .com .org .de .net .uk   » more ...

Domains Actived Recently

   » Revo.com (4 day ago)

   » Bobbyjonesband.com (18 hours ago)

   » 1stchoiceautosllc.com (16 hours ago)

   » Huishoubao.com (2 day ago)

   » M1file.com (1 day ago)

   » Renhomesantalya.com (4 day ago)

   » Napadrivertours.com (3 day ago)

   » Barefootconsultants.com (15 hours ago)

Results For Websites Listing

Found 48 Websites with content related to this domain, It is result after search with search engine

Cydanco.com

Cydanco.com   DA: 15 PA: 15 MOZ Rank: 30

  • Experience& Expertise. Cydan is the first orphan drug accelerator, trusted for our commitment to patients, known for our understanding of science and sought after for our expertise in drug and business development

Cydan NEA New Enterprise Associates

Nea.com   DA: 11 PA: 17 MOZ Rank: 29

  • Orphan drug accelerator that identifies and de-risks programs with therapeutic and commercial potential

A Novel, Highly Potent And Selective Phosphodiesterase-9

Pubmed.ncbi.nlm.nih.gov   DA: 23 PA: 10 MOZ Rank: 35

  • The most common treatment for patients with sickle cell disease (SCD) is the chemotherapeutic hydroxyurea, a therapy with pleiotropic effects, including increasing fetal hemoglobin (HbF) in red blood cells and reducing adhesion of white blood cells to the vascular endothelium

Our Portfolio Pfizer

Pfizer.com   DA: 14 PA: 43 MOZ Rank: 60

  • eFFECTOR is a clinical stage biopharmaceutical company pioneering the discovery and development of selective translation regulators as a new class of small molecule drugs for treating cancer
  • The company’s investigational compounds are designed to restore translational control to

PFIZER VENTURES TEAM HOW WE WORK Ventures Barbar • …

Cdn.pfizer.com   DA: 14 PA: 50 MOZ Rank: 68

cydanco.com eFFECTOR Therapeutics San Diego, CA effector.com Epic Sciences La Jolla, CA epicsciences.com EvolveImmune Therapeutics Westport, CT evolveimmune.com FoRx Therapeutics Basel, Switzerland forxtherapeutics.com G-CON Manufacturing Bryan, TX gconbio.com Imara Cambridge, MA imaratx.com ImCheck Therapeutics Marseille, France

Edward Conner

Zoominfo.com   DA: 16 PA: 27 MOZ Rank: 48

  • Chief Medical Officer at Locanabio
  • Edward Conner is a Chief Medical Officer at Locanabio based in San Diego, California
  • Previously, Edward was a Head Senior VP, Gene Therapy Medical & Development at Astellas Pharma and a

Cydan Development, Inc.

Cmocro.com   DA: 14 PA: 45 MOZ Rank: 65

  • Cydan is an orphan drug accelerator that identifies and de-risks programs with therapeutic and commercial potential
  • Cydan takes advantage of recent scientific breakthroughs in rare diseases and leveraging a creative approach to drug development and operates in an externally focused, highly collaborative, and capital efficient manner
  • Cydan Development, Inc., CMOCRO, PharmaCircle, …

Cydan Company Profile

Craft.co   DA: 8 PA: 6 MOZ Rank: 21

  • Cydan has 7 employees at their 1 location and $60 m in total funding,
  • See insights on Cydan including office locations, competitors, revenue, financials, executives, subsidiaries and more at …

Cydan Development Announces Formation Of Imara Inc. With

Imaratx.com   DA: 11 PA: 50 MOZ Rank: 69

  • Cambridge, Mass., April 14, 2016 – Cydan Development, Inc., an orphan drug accelerator dedicated to creating therapies that improves the lives of people living with rare genetic diseases, today announced the launch of Imara, Inc.This is the second orphan drug company launched by Cydan since 2015
  • Imara will develop IMR-687, a disease-modifying therapeutic selected specifically for the

Cydan Company Profile: Valuation & Investors PitchBook

Pitchbook.com   DA: 13 PA: 26 MOZ Rank: 48

  • Other Industries. Discovery Tools (Healthcare) Biotechnology

Cydan, A New Orphan Drug Accelerator, Launches With $16

Nea.com   DA: 11 PA: 50 MOZ Rank: 71

  • Cydan was launched in 2013 by a management team with extensive drug development and commercialization experience and with financing from leading investors NEA, Pfizer Venture Investments and Alexandria Real Estate Equities
  • The accelerator is based in Cambridge, Mass
  • For more information, please visit www.cydanco.com.

James McArthur

Linkedin.com   DA: 16 PA: 26 MOZ Rank: 53

  • www.CydanCo.com Show more Show less President of Research & Development, Founder Cydan II, Inc
  • Dec 2012 - Sep 2017 4 years 10 months
  • Cambridge, MA Cydan, LLC is …

Cydan VentureRadar

Ventureradar.com   DA: 20 PA: 50 MOZ Rank: 82

Cydan was founded in 2013 by a management team with extensive drug discovery, clinical development and business development experience and is financed by leading life sciences investors including New Enterprise Associates (NEA), Pfizer Venture Investments, Lundbeckfond Ventures, Longitude Capital, and Alexandria Venture Investments.

Cydan LinkedIn

Linkedin.com   DA: 16 PA: 14 MOZ Rank: 43

  • Cydan | 673 followers on LinkedIn
  • Cydan is the first orphan drug accelerator dedicated to advancing therapies that improve the lives of patients with rare | Cydan is an orphan drug accelerator

Jobs With Cydan

Biospace.com   DA: 16 PA: 23 MOZ Rank: 53

  • Show jobs for this employer About Cydan Cydan is an orphan drug accelerator that identifies and de-risks programs with therapeutic and commercial potential
  • Cydan takes advantage of recent scientific breakthroughs in rare diseases and leveraging a creative approach to drug development and operates in an externally

Mallinckrodt PharamceuticalsNational Niemann-Pick Disease

Nnpdf.org   DA: 9 PA: 39 MOZ Rank: 63

  • Cydan is financed by leading life sciences investors NEA, Pfizer Venture Investments, Lundbeckfond Ventures, Bay City Capital and Alexandria Venture Investments
  • The accelerator is based in Cambridge, Massachusetts
  • For more information, visit www.cydanco.comor contact Cydan at [email protected]cydanco.com
  • Corporate Contact: Ravi Venkataramani, Ph.D.

Cydan Expands Team To Accelerate Development Of Innovative

Businesswire.com   DA: 20 PA: 50 MOZ Rank: 86

BARBARA DALTON, PHD Ventures

Cdn.pfizer.com   DA: 14 PA: 50 MOZ Rank: 81

cydanco.com CytomX Therapeutics South San Francisco, CA cytomx.com eFFECTOR Therapeutics San Diego, CA effector.com Epic Sciences La Jolla, CA epicsciences.com EvolveImmune Therapeutics Westport, CT evolveimmune.com FoRx Therapeutics Basel, Switzerland forxtherapeutics.com G-CON Manufacturing Bryan, TX gconbio.com Imara Cambridge, MA

Inter-assay Variability Influences Migalastat Amenability

Pubmed.ncbi.nlm.nih.gov   DA: 23 PA: 10 MOZ Rank: 51

  • Electronic address: [email protected]cydanco.com
  • PMID: 31036492 DOI: 10.1016/j.ymgme.2019.04.005 Abstract Fabry disease is a lysosomal storage disorder caused by mutations in the GLA gene that encodes for the lysosomal enzyme α-galactosidase A (α-Gal A)
  • Reduced or absent α-Gal A activity leads to substrate accumulation and deleterious effects in

Cydan Raises $34 Million To Accelerate New Treatments For

Businesswire.com   DA: 20 PA: 50 MOZ Rank: 89

Cydan announced a new round of financing, raising a committed $34 million to advance the company’s mission to create new treatments for rare diseases.

CyclodextrinNational Niemann-Pick Disease Foundation, Inc

Nnpdf.org   DA: 9 PA: 50 MOZ Rank: 79

  • Cydan is financed by leading life sciences investors NEA, Pfizer Venture Investments, Lundbeckfond Ventures, Bay City Capital and Alexandria Venture Investments
  • The accelerator is based in Cambridge, Massachusetts
  • For more information, visit www.cydanco.comor contact Cydan at [email protected]cydanco.com.

De#risking*Orphan*Drugs:* AUnique*Ini5a5ve*for*Advancing

Plg-group.com   DA: 17 PA: 50 MOZ Rank: 88

•De#risking:+$26Mfinancing+in+2013+ securedfrom NEA, Pfizer’Ventures,’ Lundbeckfond,’Bay’City’Capital’(BCC),’AlexandriaInvestments’for’deD

Orphan Drug Accelerator Cydan Expands Transactional

Venturebeat.com   DA: 15 PA: 50 MOZ Rank: 87

  • For more information, please visit www.cydanco.com or contact Cydan at [email protected]cydanco.com
  • LaVoieHealthScience Kristina Coppola, 617-374-8800 ext

Cydan II Inc.

Biocentury.com   DA: 18 PA: 23 MOZ Rank: 64

  • Business: Pharmaceuticals Hired: Vered Bisker-Leib as CBO, formerly executive director and global head of business development for the cardiovascular and metabolic franchises at Bristol-Myers Squibb Co

Cydan Announces The Promotion Of James McArthur, Ph.D. To

Baycitycapital.com   DA: 18 PA: 50 MOZ Rank: 92

  • Cambridge, MA — Cydan Development, Inc., an orphan drug accelerator dedicated to creating therapies that improve the lives of people living with rare genetic diseases, announced the promotion of James McArthur, Ph.D
  • to president, research and development

RDR Challenge INDUSTRY SPONSORS AIM BACKGROUND …

Ejprarediseases.org   DA: 23 PA: 50 MOZ Rank: 98

  • Contact person: jmcarthur(at)cydanco.com AIM To develop and validate an assay for screening genes and/or compounds that modulate instability of microsatellite repeats
  • The rarity of repeat expansion/contraction events, estimated to be <1 per 10,000 DNA molecules, creates many challenges for assay development

Neurological Disorders

Tgen.org   DA: 12 PA: 33 MOZ Rank: 71

  • From Alzheimer's to ALS - from concussions and other traumatic brain injuries to stroke - TGen's Neurogenomics Division seeks answers to both common and rare neurological disorders
  • TGen's Center for Noninvasive Diagnostics looks for early warning signs of medical conditions, while TGen's Center for Rare Childhood Disorders is diagnosing pediatric ailments at nearly twice the national average.

Cydan’s Competitors, Revenue, Number Of Employees, Funding

Owler.com   DA: 13 PA: 16 MOZ Rank: 56

  • Cydan's top competitors include Regulus, Arcturus Therapeutics and Avidity Biosciences
  • See the full list of Cydan competitors, plus revenue, employees, and funding info on Owler, the world’s largest community-based business insights platform.

RDR Challenge INDUSTRY SPONSORS AIM BACKGROUND …

Ejprarediseases.org   DA: 23 PA: 50 MOZ Rank: 22

  • Contact person: [email protected]cydanco.com AIM To develop and validate an assay for screening genes and/or compounds that modulate instability of microsatellite repeats
  • The rarity of repeat expansion/contraction events, estimated to be <1 per 10,000 DNA molecules, creates many challenges for assay development

Cydan, A New Orphan Drug Accelerator, Launches With $16

Fiercebiotech.com   DA: 21 PA: 50 MOZ Rank: 100

  • Cydan, a New Orphan Drug Accelerator, Launches with $16 Million Financing from Leading Investors NEA, Pfizer Venture Investments and Alexandria Real Estate Equities Cambridge, Mass

Cydan Announces Formation Of Tiburio Therapeutics Inc. To

Biospace.com   DA: 16 PA: 50 MOZ Rank: 96

  • CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Cydan today announced the launch of Tiburio Therapeutics Inc
  • (Tiburio), a private biopharmaceutical company focused on developing treatments for rare neuroendocrine tumors and rare endocrine diseases.Tiburio will advance two compounds licensed from Ipsen for the treatment of non-functioning pituitary adenoma (NFPA) (TBR-760) and for …

Niels Svenstrup, Cydan Development Inc: Profile And

Bloomberg.com   DA: 17 PA: 24 MOZ Rank: 72

  • Niels Svenstrup is Senior VP:Dev at Cydan Development Inc
  • See Niels Svenstrup's compensation, career history, education, & memberships.

Citybizlist : Washington DC : NEA-backed Cydan Appoints

Dc.citybizlist.com   DA: 18 PA: 50 MOZ Rank: 100

  • CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cydan today announced that Imran A
  • Babar, PhD, has been named to the leadership team as chief business officer to help the company advance new and innovative therapies for patients living with rare monogenetic diseases.Dr
  • Babar joins the company from OrbiMed Advisors, which is a leading healthcare-dedicated investment firm.

Accelera’ng*Orphan*Drug*Opportuni’es*

Bio-m.org   DA: 13 PA: 50 MOZ Rank: 96

ConfidenFal’ 4 CydanStructure Investorsfund Cydan,LLC* • *CydanLLCforms Cydan’Developmentas’100%’ owned’C’Corp’subsidiary’ Cydan,*LLC*Funds*CydanDevelopment

Orphan Drug Accelerator Cydan Supports Rare Disease Day

Venturebeat.com   DA: 15 PA: 50 MOZ Rank: 99

  • For more information, please visit www.cydanco.com or contact Cydan at [email protected]cydanco.com
  • Media Contact: LaVoieHealthScience Kristina Coppola, 617-374-8800 ext

Citybizlist : Washington DC : Cydan Raises $34 Million

Dc.citybizlist.com   DA: 18 PA: 48 MOZ Rank: 15

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cydan today announced a new round of financing, raising a committed total of $34 million to advance the company’s efforts to create new and innovative therapies for patients living with rare genetic diseases.New investor, Longitude Capital, joins Cydan’s existing investors, New Enterprise Associates (NEA), who led the round, along with Pfizer Venture

Citybizlist : Boston : Cydan Raises $34 Million From NEA

Boston.citybizlist.com   DA: 22 PA: 48 MOZ Rank: 14

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cydan today announced a new round of financing, raising a committed total of $34 million to advance the company’s efforts to create new and innovative therapies for patients living with rare genetic diseases.New investor, Longitude Capital, joins Cydan’s existing investors, New Enterprise Associates (NEA), who led the round, along with Pfizer Venture

Citybizlist : Baltimore : NEA-backed Cydan Appoints Imran

Baltimore.citybizlist.com   DA: 25 PA: 50 MOZ Rank: 13

  • CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cydan today announced that Imran A
  • Babar, PhD, has been named to the leadership team as chief business officer to help the company advance new and innovative therapies for patients living with rare monogenetic diseases.Dr
  • Babar joins the company from OrbiMed Advisors, which is a leading healthcare-dedicated investment firm.

Longitudecapital.com (Longitude Capital: Venture Growth

Host.io   DA: 7 PA: 21 MOZ Rank: 66

  • Longitude Capital is a healthcare venture capital firm that invests in transformative healthcare companies to unlock value and enable growth

Cydan Development Announces The Acquisition Of Its First

Pipelinereview.com   DA: 18 PA: 50 MOZ Rank: 11

  • CAMBRIDGE, MA, USA I April 3, 2017 I Cydan Development, Inc., an orphan drug accelerator dedicated to creating therapies that improve the lives of people living with rare genetic diseases, today announces that Vtesse, Inc., its first rare disease spin-out company, has been acquired by Sucampo Pharmaceuticals, Inc
  • Following a collaboration with the National Center for …

Orphan Drug Accelerator Cydan Expands Transactional

Fiercebiotech.com   DA: 21 PA: 50 MOZ Rank: 10

  • For more information, please visit www.cydanco.com or contact Cydan at [email protected] Contacts
  • LaVoieHealthScience Kristina Coppola, 617-374-8800 ext

Cydan Raises $31 Mln In Series A Funding PE Hub

Pehub.com   DA: 13 PA: 9 MOZ Rank: 63

  • raised $31 million in Series A funding from New Enterprise Associates, Pfizer Venture Investments, Lundbeckfond Ventures, Bay City Capital and Alexandria Venture Investments.

Recently Analyzed Sites

Revo.com (4 day ago)

Bobbyjonesband.com (18 hours ago)

1stchoiceautosllc.com (16 hours ago)

Huishoubao.com (2 day ago)

M1file.com (1 day ago)

Trekksoft.com (4 day ago)

Tibbo.com (16 hours ago)

Urdusa.com (2 seconds ago)

Tailspinbandsc.com (3 day ago)

Dungscanada.com (1 day ago)

Jfsorange.org (3 day ago)

Marloweslu.com (2 day ago)